IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Pfizer and Ranbaxy Settle Lipitor Patent Dispute

11:37 AM MDT | June 23, 2008 | Deepti Ramesh

Pfizer (New York) and Ranbaxy Laboratories Ltd. (Gurgaon) say they have settled their patent dispute involving Pfizer’s Lipitor, the largest selling cholesterol-lowering drug worldwide with sales of $12.7 billion. The agreement provides Ranbaxy with a license to sell Atorvastatin, the generic version of Lipitor, in the U.S. starting November 30, 2011, and in Australia, Belgium, Canada, Germany, Italy, the Netherlands, and Sweden starting at various dates, the firms say. The agreement follows unconfirmed media reports earlier this month regarding the...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa